Search by conditions:

 

Protocol Description Phase
16-510 A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Patients with Unresectable or Metastatic B7-H3-Expressing Neoplasms and Neoplasms whose Vasculature Expresses B7-H3  (View details on clinicaltrial.gov) Phase I
18-002 A Phase 1, Open Label, Dose Escalation Study of MGD009, a Humanized B7-H3 x CD3 DART® Protein, in Combination with MGA012, an anti-PD-1 antibody, in Patients with Relapsed or Refractory B7-H3-Expressing Tumors  (View details on clinicaltrial.gov) Phase I
19-060 A phase 1, open-label, dose escalation clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARV-110 in patients with metastatic castration-resistant prostate cancer who have progressed on at least two prior systemic therapies  (View details on clinicaltrial.gov) Phase I
16-493 A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration- Resistant Prostate Cancer and DNA-Repair Anomalies  (View details on clinicaltrial.gov) Phase II
18-117 A Phase 2 Study of PCM-075 in Combination with Abiraterone and Prednisone in Subjects with Metastatic Castration-Resistant Prostate Cancer  (View details on clinicaltrial.gov) Phase II
18-289 A Phase I, First-in-Human, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0184 Administered Daily for 21 Days to Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
14-375 A Single-arm Open Label Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer  (View details on clinicaltrial.gov) Phase II
08-207 Circulating Tumor Cell Analysis in Patients with Localized Prostate Cancer Undergoing Prostatectomy  (View details on clinicaltrial.gov) N/A
16-150 Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers  (View details on clinicaltrial.gov) Phase I
17-687 Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors  (View details on clinicaltrial.gov) Phase II
11-497 Phase III Randomized Clinical Trial of Proton Therapy vs IMRT for Low or Low-intermediate Risk Prostate Cancer  (View details on clinicaltrial.gov) Phase III
18-139 TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency  (View details on clinicaltrial.gov) Phase II
18-146 TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency  (View details on clinicaltrial.gov) Phase III
13 clinical trials listed

Back to Top